These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30474478)

  • 1. Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients.
    Lau CW; Martens P; Lambeets S; Dupont M; Mullens W
    Acta Cardiol; 2019 Oct; 74(5):405-412. PubMed ID: 30474478
    [No Abstract]   [Full Text] [Related]  

  • 2. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.
    Martens P; Lambeets S; Lau CW; Dupont M; Mullens W
    Acta Cardiol; 2019 Apr; 74(2):115-122. PubMed ID: 29909743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test.
    Malfatto G; Ravaro S; Caravita S; Baratto C; Sorropago A; Giglio A; Tomaselli M; Parati G; Villani A
    Acta Cardiol; 2020 Dec; 75(8):732-736. PubMed ID: 31577528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
    Mapelli M; Mattavelli I; Paolillo S; Salvioni E; Magrì D; Galotta A; De Martino F; Mantegazza V; Vignati C; Esposito I; Dell'Aversana S; Paolillo R; Capovilla T; Tamborini G; Nepitella AA; Filardi PP; Agostoni P
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1173-1184. PubMed ID: 37368004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
    Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
    J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study.
    Beltrán P; Palau P; Domínguez E; Faraudo M; Núñez E; Guri O; Mollar A; Sanchis J; Bayés-Genís A; Núñez J
    Int J Cardiol; 2018 Feb; 252():136-139. PubMed ID: 29249422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
    Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms.
    Maury E; Belmans A; Bogaerts K; Vancayzeele S; Jansen M
    Sci Rep; 2024 Jun; 14(1):13512. PubMed ID: 38866873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy.
    Gonçalves AV; Pereira-da-Silva T; Galrinho A; Rio P; Soares R; Feliciano J; Moreira RI; Silva S; Alves S; Capilé E; Ferreira RC
    Arq Bras Cardiol; 2020 Nov; 115(5):821-827. PubMed ID: 33084746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
    Dereli S; Kılınçel O; Çerik İB; Kaya A
    Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
    [No Abstract]   [Full Text] [Related]  

  • 17. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
    JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
    Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
    Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.